All lobbying filings

Forbes-Tate

Forbes-Tate filed a Q3 termination report for Ultragenyx Pharmaceutical on October 20, 2026, reporting $20,000 in lobbying income.

Lobbying for Ultragenyx Pharmaceutical · Clinical-state biopharmaceutical company

As filed: FORBES-TATE for ULTRAGENYX PHARMACEUTICAL.

All filings by Forbes-Tate · Everything Ultragenyx Pharmaceutical has reported

Filing · LD-2 quarterly report Q3 termination

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$20,000

What the client paid this registrant for the period.

Client based in

California

Representation ended

Aug 31, 2026

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to drug development and market access.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.